TrialClinical and translational science2025

Mirikizumab Pharmacokinetics and Exposure-Response in Patients With Moderately-To-Severely Active Crohn's Disease: Results From Two Randomized Studies.

Laiyi Chua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.